Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19

1 February 2021

journal article
editorial
Published by American College of Physicians in Annals of Internal Medicine

Vol. 174 (2), JC16
https://doi.org/10.7326/acpj202102160-016

Abstract

Source Citation Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333-44. 33085857 Clinical Impact Ratings Hospitalists: 6 out of 7 Infectious Disease: 6 out of 7 Critical Care: 7 out of 7 Pulmonology: 6 out of 7

This publication has 4 references indexed in Scilit:

Covid-19: Critically ill patients treated with arthritis drug tocilizumab show improved outcomes, researchers report
Published by BMJ ,2020
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
JAMA, 2020
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
The Oncologist, 2018
Sepsis biomarkers: a review
Critical Care, 2010